Loading company…
Tioma Therapeutics, Inc. develops anti-CD47 antibodies for solid and hematologic cancers, based in St. Louis, US.
Based in St. Louis, US, Tioma Therapeutics, formerly known as Vasculox, focuses on immuno-oncology and anti-CD47 antibodies for solid and hematologic cancers. It was founded by William Frazier, and John Donovan is president and CEO. In August 2016, Novo Ventures, RiverVest Ventures, Roche Venture Fund and SR One co-led a USD 86 million Series A round.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in